Ruoke Wang

TL;DR: In a study of antibodies isolated from patients infected with SARS-CoV-2, antibodies that potently neutralized the virus competed with angiotensin-converting enzyme 2 for binding to the receptor-binding domain of the viral spike protein, suggesting that antibodies that disrupt this interaction could be developed to treat Sars-Cov-2 infection.

TL;DR: Results suggest that antibody response to RBDs is viral species-specific while that cross-recognition target regions outside the RBD are cross- Recognition target areas outside the SARS-CoV-2.

TL;DR: Two potent human RBD-specific neutralizing monoclonal antibodies (MERS-4 and MERS-27) derived from single-chain variable region fragments of a nonimmune human antibody library are reported, providing hope for a therapy for a potentially emerging pandemic where none currently exists.

TL;DR: In this article, the authors showed that the South African variant B.1.351 was the most resistant to current monoclonal antibodies and convalescent plasma from coronavirus disease 2019 (COVID-19)-infected individuals.

TL;DR: In this paper, the top three most potent yet variable neutralizing antibodies for SARS-CoV-2 infection in Ad5-hACE2-sensitized mice were identified.